Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $16.71, but opened at $16.09. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $16.09, with a volume of 4,499 shares traded.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on TLX. William Blair reiterated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th. UBS Group increased their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 27th.
View Our Latest Analysis on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 0.4 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Best Stocks Under $10.00
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Canadian Penny Stocks: Can They Make You Rich?
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Technology Stocks Explained: Here’s What to Know About Tech
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.